CuraVac, Inc. is a clinical-stage biopharmaceutical company focused on the development of a new class of immunotherapies for treating autoimmune and inflammatory diseases including myasthenia gravis (MG), multiple sclerosis (MS) and other diseases. The company’s independent advisory board includes Jean-Paul Prieels, PhD, previously head of research at GSK Biologicals, Didier Hoch, PhD, previously chairman of Sanofi Pasteur MSD, Bruce Forrest, M.D., previously senior vice president at Wyeth Pharmaceuticals, and Prof. Marc de Baets, M.D., PhD, clinical neurologist and MG expert at Maastricht University Hospital. CuraVac is the scientific coordinator and the commercial partner of the Myasterix consortium, which receives funding under the European Union’s Seventh Framework Program.